Long-Acting Intelligence

The living market intelligence system for Long-Acting Injectables.

Vectora structures the entire LAI ecosystem — every company, drug, candidate and technology — into one source your team can explore, monitor and build on.

The problem

Long-acting injectables are scattered across sources — and generalist tools treat them as a subset of injectables.

The information lives across FDA filings, ClinicalTrials.gov, PubMed and corporate press. No generalist platform gives long-acting injectables a scope of their own, so reassembling the picture — source by source, name by name — falls on the analyst.

Vectora structures it once, so it can be queried — not rebuilt by hand.
The difference

LAI, treated as its own field — not a subset of injectables.

Generalist tools file long-acting injectables under “injectables” and stop there. Vectora draws the line they don’t: it defines the LAI landscape as its own field, structures it as a queryable ontology, and keeps it live — the current state of every player, and the events that change it. You can slice the field any way you need — by technology, phase, indication or authority — instead of rebuilding it each time.

The only structured, queryable map of the Long-Acting Injectables landscape.
Coverage & grain

One ecosystem, modeled two ways.

Every company, marketed drug, clinical candidate, trademark, proprietary delivery technology, target and indication in the LAI landscape — defined, curated and resolved into one queryable ontology.

Assets — map the field

Every molecule, marketed and in the pipeline.

Each asset is a molecule × delivery technology × developer. Size the landscape and segment it — by phase, technology, target or modality.

Products by market — compare what’s live

Every brand, by regulatory authority.

Each product is a brand × authority. Read the real regulatory profile — FDA against EMA, label by label.

The dimensions you can cross
Delivery technology
MicrosphereNanocrystalIn-situ depotImplantLiposomeOil depotProdrug / esterMatrix materialPEGylationLipidationAlbumin-bindingFc-fusion
Molecule
API classModalityTargetRouteLocal vs systemic effectMW / logP / PSA
Clinical
Therapeutic areaIndicationDevelopment phaseDuration of actionDosing interval
Regulatory — FDA & EMA
Approval by authorityBoxed warningCold chainStorageInjection sitesVolumesStrengthsExcipients
Every dimension shows how completely it is documented across the scope — so you always know how complete a given view is.
One platform, three products

Explore, monitor, produce.

One substrate feeds all three products, each unlocked for your organization as it becomes available.

Available

Atlas

Explore the landscape. Scope a population, compare molecules or products, read FDA against EMA in one view.

Coming

Inbox

A periodic brief of LAI events — readouts, approvals, deals — filtered to the field.

Planned

Studio

Briefs and reports generated on demand — each claim traceable to its source.

Atlas explores · Inbox monitors · Studio produces.
Atlas · Available

Explore the landscape from every angle.

Filter the landscape to the assets you care about, then read it through a lens: a table, a competitive landscape, market trends over time, a positioning map — and a side-by-side comparison of two to six items, FDA against EMA.

Sourced by default. Regulatory facts link to their official FDA and EMA labels — and no value is ever invented to fill a blank.

Atlas Compare view — four brands side by side, FDA and EMA labels with divergences highlighted
Compare — up to six brands side by side, FDA against EMA, divergences highlighted (here, the same brand is Otsuka on FDA and Lundbeck on EMA).
Delivery-technology families by route, heatmap
Delivery-technology families × route. Dark cells are market gaps.
Market growth by therapeutic area over time
Market growth by therapeutic area, 1952 to today.
API class by physical release family, heatmap shaded by market share
API class × release family, shaded by market share.
Duration-of-action mix, 2010 versus 2024
Duration-of-action mix, 2010 vs 2024.
For your team

Built for the questions each team asks.

The same substrate, read through the lens of each role.

Business Development
“Who competes directly in Phase 3 schizophrenia LAIs — and who develops them?”
Competitive Intelligence
“In long-acting antipsychotics, do big pharma or specialists lead?”
Medical Affairs
“Which LAIs reach a six-month dosing interval, and in which indications?”
Regulatory
“For this brand, what differs between the FDA and the EMA label?”
Marketing
“How many approved LAIs need cold-chain storage — and in what presentations?”
R&D / Strategy
“Where are the white spaces — which technology × indication crossings have no asset yet?”
The analyst behind Vectora
Franck Issartel, PharmD

Franck Issartel, PharmD

Eleven years in pharmaceutical competitive intelligence.

Vectora encodes that domain work — the scope, the ontology, the delivery-technology taxonomy — into the substrate itself. In a specialized field, the analysis is only as strong as the domain knowledge behind it.

You work directly with the analyst who builds and maintains the substrate — not an account manager relaying your questions.

Now onboarding design partners.

Vectora is opening to a first group of LAI teams as design partners. Tell us about your work and we’ll be in touch.

Request access